Pharmaceutical group Lundbeck came out of the second quarter with better revenue and earnings than expected in the stock market. The company maintains its expectations for the whole of 2026.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Pharmaceutical group Lundbeck came out of the second quarter with better revenue and earnings than expected in the stock market. The company maintains its expectations for the whole of 2026.